Advertisement

Topics

Ipsen Announces Data Presentations of Lanreotide (Somatuline® Autogel®), Telotristat Ethyl and the Investigational Compound 177Lu-OPS201 at the European Neuroendocrine Tumor Society (ENETS) 2017 Conference

01:00 EST 9 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical group, today announced that Somatuline® Autogel® (lanreotide), telotristat ethyl and the investigational compound 177Lu-OPS2...

Other Sources for this Article

For further information:
Ipsen
Media
Didier Véron
Senior Vice-President, Public Affairs
and Communication
Tel.: +33 (0)1 58 33 51 16
E-mail: didier.veron@ipsen.com
or
Financial Community
Eugenia Litz
Vice-President Investor Relations
Tel.: +44 (0) 1753 627721
E-mail: eugenia.litz@ipsen.com
or
Brigitte Le Guennec
Corporate External Communication Manager
Tel.: +33 (0)1 58 33 51 17
E-mail : brigitte.le.guennec@ipsen.com
or
Côme de La Tour du Pin
Investor Relations Executive
Tel.: +33 (0)1 58 33 53 31
E-mail: come.de.la.tour.du.pin@ipsen.com

NEXT ARTICLE

More From BioPortfolio on "Ipsen Announces Data Presentations of Lanreotide (Somatuline® Autogel®), Telotristat Ethyl and the Investigational Compound 177Lu-OPS201 at the European Neuroendocrine Tumor Society (ENETS) 2017 Conference"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...